Today’s Forbes Daily covers Eli Lilly’s historic loss, the new GPT-5 for OpenAI’s ChatGPT, reactions to Instagram’s new map ...

Those on the highest 36 mg dose of the medicine on average lost 12.4 per cent of their body weight at 72 weeks ...

Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...

Shares of Novo Nordisk climbed 4.29% during Friday’s pre-market trading session, after rival Eli Lilly’s Phase 3 ATTAIN-1 ...

This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

* U.S. President Donald Trump has the so-called 'BRIC' group of nations directly in his trade war crosshairs, slapping ...

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short of market expectations.

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

The S&P 500 may have stalled on Thursday, but the Nasdaq hit a new high, as a week of positive earnings surprises and rising ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

The iPhone maker's shares [rallied for a second day]( ...